Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Daiichi Sankyo
QuintilesIMS
Merck
Julphar
Cerilliant
US Army
UBS
Healthtrust

Generated: November 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021081

« Back to Dashboard

NDA 021081 describes LANTUS SOLOSTAR, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from five suppliers. There are seventeen patents protecting this drug. Additional details are available on the LANTUS SOLOSTAR profile page.

The generic ingredient in LANTUS SOLOSTAR is insulin glargine recombinant. There are forty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin glargine recombinant profile page.
Summary for 021081
Tradename:LANTUS SOLOSTAR
Applicant:Sanofi Aventis Us
Ingredient:insulin glargine recombinant
Patents:20
Pharmacology for NDA: 021081
Ingredient-typeInsulin
Suppliers and Packaging for NDA: 021081
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 NDA sanofi-aventis U.S. LLC 0088-2219 0088-2219-00 1 SYRINGE in 1 CARTON (0088-2219-00) > 3 mL in 1 SYRINGE
LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 NDA sanofi-aventis U.S. LLC 0088-2219 0088-2219-00 1 SYRINGE in 1 CARTON (0088-2219-00) > 3 mL in 1 SYRINGE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength100 UNITS/ML
Approval Date:Apr 20, 2000TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jan 23, 2024Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Dec 13, 2023Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Mar 23, 2028Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021081

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081-001 Apr 20, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081-001 Apr 20, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Medtronic
US Army
Covington
UBS
Mallinckrodt
Baxter
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.